Sera Prognostics Inc (SERA) Q3 2024 Earnings Call Transcript Summary
Sera Prognostics Inc (SERA) Q3 2024 Earnings Call Transcript Summary
Net loss for Q3 2024 increased to $7.9 million from $7.2 million in Q3 2023.The following is a summary of the Sera Prognostics Inc (SERA) Q3 2024 Earnings Call Transcript:
以下是Sera Prognostics Inc（SERA）2024年第三季度業績會議記錄摘要：
Financial Performance:
財務表現：
Net revenue for Q3 2024 was $29,000, a decrease from $42,000 in the same period a year ago.
Total operating expenses for Q3 2024 were $8.9 million, up 8% from $8.2 million in Q3 2023.
Net loss for Q3 2024 increased to $7.9 million from $7.2 million in Q3 2023.
2024年第三季度淨營業收入爲29,000美元，較一年前的42,000美元下降。
2024年第三季度總營業費用爲890萬美元，比2023年第三季度的820萬美元增長了8%。
2024年第三季度淨虧損從2013年第三季度的720萬美元上升至790萬美元。
Business Progress:
業務進展：
Focused on publication of clinical trial results and expanding test adoption and payer coverage.
Launched educational campaigns with significant engagement and initiated direct-to-consumer sales through new online platforms.
Continued growth in visibility and adoption through media campaigns and social media presence.
專注於發佈臨床試驗結果並擴大測試採用率和支付者覆蓋範圍。
通過新的在線平台啓動了具有重大參與度的教育宣傳活動，並推出了直接面向消費者銷售。
通過媒體宣傳和在社交媒體上的存在，能夠進一步提升知名度和用戶採用率。
Opportunities:
機會：
Addressing increased rates of preterm births in the U.S., a significant health care challenge, via educational and awareness campaigns.
Expanding direct-to-consumer access to PreTRM tests, enhancing potential for revenue growth.
通過教育和意識活動來應對美國早產率上升，這是一個重要的醫療保健挑戰。
擴大直接面向消費者推廣PreTRm檢測，提升營業收入增長潛力。
Risks:
風險：
Slow scaling of AI services may delay expected revenue growth from these innovations.
人工智能服務的緩慢擴展可能會延遲這些創新預期營業收入增長。
Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：本文由人工智能生成。內容準確性無法完全保證。如需更全面詳情，請參閱IR網站。本文僅供投資者參考，不具有任何指導或推薦建議。
